Diagnostic value of short-duration head-up tilt test for unexplained syncope: a non-inferiority study Authors: Saijia Yang, Yuen Liang, Zhuoshan Huang, Lin Wu, Ruimin Dong, Kemei Liu, Shan Cao, Ling Jiang, Xujing Xie Published: 2026 ABSTRACT AbstractBackgroundThe traditional head-up tilt test (HUTT) is time-consuming, imposing a noticeable burden on patients and on high-throughput syncope clinics. A 20-minute “Fast Italian Protocol,” introduced in 2023, promises to streamline the procedure, yet its diagnostic reliability—particularly the optimal length of the sublingual nitroglycerin head-up tilt test (SNHUT) segment—remains unclear.MethodsBetween 2019 and 2025 we assessed 1,218 consecutive patients with unexplained syncope. Individuals were allocated non-randomly to a short protocol (10-minute baseline head-up tilt test (BHUT) + 20-minute SNHUT; n = 393) or the conventional protocol (20-minute BHUT + 20-minute SNHUT; n = 825). A one-sided non-inferiority analysis (α = 0.025; margin = − 10%) provided 90.7% statistical power.ResultsOverall positivity did not differ between the short and conventional protocols (53.4% vs. 57.3%, p = 0.20), nor did the distribution of vasovagal reaction types (all p > 0.05). In the abbreviated arm, 86.4% of positive responses emerged within the first 10 min of tilt or nitroglycerin exposure, and 98.9% appeared within 15 min—proportions virtually identical to those observed with the conventional protocol (88.9% and 98.9%, respectively; p = 0.49).ConclusionA 10-minute BHUT followed by a 20-minute SNHUT is diagnostically non-inferior to the standard 40-minute test. Furthermore, curtailing the SNHUT phase to 15 min retains 98.9% of positive findings while trimming total test time by 37.5%. This streamlined approach could ease patient burden and significantly boost throughput in high-volume syncope centers.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-026-05846-1.Keywords: Head-up tilt test, Nitroglycerin, Vasovagal syncope, Positivity, Short-duration protocol Introduction Syncope is a common clinical symptom which is defined by transient loss of consciousness (TLOC) resulting from sudden cerebral hypoperfusion. Episodes are typically self-limiting and benign, with first-onset syncope displaying a bimodal age distribution [1, 2]. Epidemiological data indicate that as high as 15%–20% of children and adolescents experience at least one syncopal episode [3], and adolescent patients show significantly elevated rates of depression, anxiety, and conversion disorders [4]. A meta-analysis of 23 studies on 3,593 vasovagal syncope (VVS) patients in 2021 reported injury rates of 25.7% among younger individuals (< 50 years) and 43.4% among elderly patients, with 13.9% sustaining severe injuries [5]. Based on assumed 70-year life expectancy, the prevalence of syncope is estimated at 42% and syncope corresponds to 3% to 5% of emergency department visits [6]. Prolonged head-up tilt testing (HUTT) consumes laboratory capacity and lengthens patient waiting times, particularly in centres that perform several hundred HUTTs annually. Following an initial episode, the probability of remaining recurrence-free declines steadily over time [7]. Given the condition’s recurrent nature and potential to cause disability [8, 9], accurate and timely diagnosis is essential. Syncope is typically categorized into three major types: neurally mediated reflex syncope (commonly referred to as vasovagal syncope), orthostatic hypotension and orthostatic intolerance syndromes, and cardiac syncope. Current guidelines from the American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS 2017) [10] and the European Society of Cardiology (ESC 2018) [11] endorse HUTT as a first-line diagnostic tool (Class IIa recommendation) for patients with unexplained syncope, particularly when VVS is suspected [12]. HUTT induces hemodynamic instability by redistributing blood through gravitational forces, thereby activating the Bezold–Jarisch reflex [13]. This leads to sympathetic inhibition, vagal overactivation, and consequent cerebral hypoperfusion, reproducing typical prodromal symptoms such as pallor, diaphoresis, blurred vision, and transient visual loss [10, 14]. Since its first clinical application in 1986, the test has undergone progressive shortening to reduce procedural burden while maintaining diagnostic accuracy—from the original 60-minute European protocol [15] to the 35-minute “Italian protocol” (20-minute baseline head-up tilt test (BHUT) + 15-minute sublingual- nitroglycerin head-up tilt test (SNHUT)) introduced in 2000 [16, 17].According to the European Society of Cardiology (ESC 2018) [11] and the 2022 Chinese Expert Consensus on Standard Application of Head-up Tilt Test [18], this study adopted a protocol consisting of a 20-minute BHUT (excluding supine time) followed by a 20-minute SNHUT.This protocol is hereafter referred to as the conventional protocol. Due to its operational simplicity and favorable safety profile—demonstrating sensitivity between 57.5% and 87% and specificity between 70% and 100% [19, 20]—sublingual nitroglycerin has supplanted intravenous isoproterenol as the standard provocative agent [21, 22]. Nitroglycerin offers a favorable safety profile, with fewer tachyarrhythmic complications than isoproterenol, but its optimal exposure time has not been fully defined. Most protocol studies originate from Europe or North America; data from Asian populations remain scarce, leaving uncertainty about generalizability. More recent investigations have continued to explore shorter test durations.For example, the “fast Italian protocol,” consisting of a 10-minute BHUT followed by a 10-minute SNHUT, was proposed by Russo et al. [23]. However, data for the optimal duration of the SNHUT phase is still limited. This ongoing quest for optimization brings us to the need to validate the diagnostic effectiveness of abbreviated protocols. The present study therefore aimed to assess whether a short-duration protocol (10-minute BHUT + 20-minute SNHUT) is non-inferior to the conventional 40-minute protocol (20-minute BHUT + 20-minute SNHUT) in patients with unexplained syncope. We also quantified potential laboratory time savings, providing a pragmatic measure for centers considering protocol adoption. Additionally, we examined the temporal distribution of positive responses to explore the potential for further refinement of SNHUT duration. Methods Study design and population This single-center, retrospective, non-randomized, historically controlled study evaluated the diagnostic value of a short-duration HUTT protocol compared to the conventional protocol. The study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Approval No. [2023]193-01; date: August 3, 2023). Informed consent was waived due to the retrospective study design. This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Between January 1, 2019, and January 31, 2025, we consecutively enrolled patients with unexplained syncope from the Third Affiliated Hospital of Sun Yat-sen University. All participants underwent a standardized preliminary evaluation, including detailed history-taking (including circumstances of syncope, prodromal symptoms, and recovery), physical examination, 12-lead electrocardiography, and echocardiography, to exclude obvious cardiac or neurological causes. Eligible patients then proceeded to HUTT. As depicted in Fig. 1, patient allocation to test protocols was determined by time of evaluation: those assessed between January 2019 and May 2023 received the conventional protocol, while patients evaluated between June 2023 and January 2025 received the short-duration protocol. Of note, the institutional diagnostic pathway and referral criteria for HUTT remained consistent throughout the entire study period from 2019 to 2025, minimizing the risk of temporal changes in patient selection. Study Flowchart. The conventional protocol group (n = 825) included patients tested between January 2019 and May 2023, while the short-duration group (n = 393) comprised patients tested from June 2023 to January 2025. A total of 1,321 patients underwent HUTT during the study period; 103 were excluded due to incomplete data (n = 12) or a confirmed diagnosis of non-vasovagal syncope (n = 91). Among the excluded patients with confirmed orthostatic hypotension (OH) (n = 58), 47 were from the conventional protocol group (38 diagnosed during BHUT, 9 during SNHUT) and 11 from the short-duration protocol group (all 11 diagnosed during BHUT) Inclusion and exclusion criteria Inclusion criteria: Clinical diagnosis of unexplained syncope; Clinical diagnosis of unexplained syncope; Complete the HUTT procedure. Complete the HUTT procedure. Exclusion criteria: Contraindications to HUTT, including severe coronary stenosis; critical aortic and/or mitral stenosis; severe hypertrophic obstructive cardiomyopathy; malignant arrhythmias; uncontrolled hypertension; significant intracranial or extracranial vascular stenosis; severe anemia; glaucoma; and pregnancy [10, 11, 24]; Contraindications to HUTT, including severe coronary stenosis; critical aortic and/or mitral stenosis; severe hypertrophic obstructive cardiomyopathy; malignant arrhythmias; uncontrolled hypertension; significant intracranial or extracranial vascular stenosis; severe anemia; glaucoma; and pregnancy [10, 11, 24]; Cases of non-vasovagal syncope (e.g., suspected false positives, psychogenic pseudosyncope, orthostatic hypotension, or orthostatic intolerance); Cases of non-vasovagal syncope (e.g., suspected false positives, psychogenic pseudosyncope, orthostatic hypotension, or orthostatic intolerance); Incomplete records or indeterminate diagnoses. Incomplete records or indeterminate diagnoses. Head-up tilt test protocol All procedures were conducted using the HUT-821 tilt table (Beijing Juchi Medical Technology Co., Ltd.) with continuous ECG monitoring via the iMEC8 electrocardiographic system (Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China). Blood pressure was monitored using an iMEC8 patient monitor with an oscillometric upper-arm cuff. Automated measurements of systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) were recorded every 3 min. Manual measurements were additionally performed at key time points: 1 min after tilting, immediately before nitroglycerin administration, at syncope onset (for positive cases), and during recovery. Short-duration protocol The short-duration HUTT protocol involved three phases: Supine rest phase: 5 minutes of baseline recording in the horizontal position. Supine rest phase: 5 minutes of baseline recording in the horizontal position. Passive tilt phase: Tilt to 70°, maintained for up to 10 minutes or until a positive response occurred. Passive tilt phase: Tilt to 70°, maintained for up to 10 minutes or until a positive response occurred. Drug provocation phase (if the passive tilt test yields a negative result): Administer 0.375 mg nitroglycerin sublingually, and maintain the tilted position for up to 20 minutes or until a positive response was observed. Drug provocation phase (if the passive tilt test yields a negative result): Administer 0.375 mg nitroglycerin sublingually, and maintain the tilted position for up to 20 minutes or until a positive response was observed. Conventional protocol The conventional protocol followed identical procedures, with both BHUT and SNHUT phases lasting 20 min each. Pediatric modifications In pediatric patients (age < 18 years), modifications included a reduced tilt angle (60°) and adjusted nitroglycerin dosage (5 µg/kg, maximum 0.3 mg), while all other parameters remained unchanged. Definition of positive response and hemodynamic classification A positive HUTT was defined by the onset of syncope or prodromal symptoms, such as pallor, diaphoresis, blurred vision, hearing impairment, amaurosis, chest tightness, fatigue, delayed responsiveness, or reduced muscle tone [6], accompanied by characteristic hemodynamic changes. Each event was classified based on the hemodynamic response pattern involving changes in blood pressure and/or heart rate [11]: Mixed type: Heart rate falls at the time of syncope but ventricular rate does not fall below 40 bpm for more than 10 s, and asystole of less than 3 s occurs. Blood pressure falls before heart rate falls. Cardioinhibitory type: Ventricular rate falls below 40 bpm for more than 10 s, or asystole occurs for more than 3 s. Blood pressure falls before or with the heart rate fall. Vasodepressor type: Heart rate does not fall more than 10% from its peak at the time of syncope. Statistical analysis Sample size calculation Sample size calculation was based on the following assumptions: a 55% positive rate in the conventional group (based on preliminary data), a non-inferiority margin of − 10%, a one-sided α level of 0.025, and 80% power. This yielded a required sample size of 389 patients per group. To account for potential data loss and the retrospective nature of the study, all eligible patients during the specified timeframe were included. This resulted in 393 patients in the short-duration group and 825 patients in the conventional group, achieving 90.7% statistical power. Justification of non-inferiority margin The non-inferiority margin was prespecified as -10% for the absolute difference in positivity rates between the short-duration and conventional HUTT protocols. The short-duration protocol would be considered non-inferior if the lower limit of the 95% confidence interval for this difference exceeded − 10%. This threshold was based on clinical consensus that a loss in diagnostic sensitivity exceeding 10% would outweigh the operational benefits of a shortened test (e.g., increased throughput, reduced technician time). This margin aligns with previous non-inferiority studies of abbreviated syncope tests [23]. Similar margins have been applied in other cardiovascular and critical care trials [25–27], supporting − 10% as a clinically meaningful boundary that balances diagnostic effectiveness with procedural efficiency. Primary and secondary endpoints The primary endpoint was the overall positive rate. Non-inferiority of the short-duration protocol was confirmed if the lower bound of the 95% confidence interval (CI) for the difference in positive rates (short-duration minus conventional) exceeded − 10%. Secondary endpoints included Positive rates during the BHUT and SNHUT phases Positive rates during the BHUT and SNHUT phases Distribution of hemodynamic response types (mixed, cardioinhibitory, vasodepressor) Distribution of hemodynamic response types (mixed, cardioinhibitory, vasodepressor) Temporal distribution of positive responses during the SNHUT phase Temporal distribution of positive responses during the SNHUT phase Subgroup analyses Predefined subgroup analyses were conducted to examine: Positive rates by test phase (BHUT vs. SNHUT) Positive rates by test phase (BHUT vs. SNHUT) Hemodynamic response patterns by test phase Hemodynamic response patterns by test phase Time-to-positive response during SNHUT (≤ 10 min, 11–15 min, ≥ 16 min). Time-to-positive response during SNHUT (≤ 10 min, 11–15 min, ≥ 16 min). These analyses were based on the hypothesis that the short-duration protocol might have different diagnostic performance in early versus late phases of testing, and that temporal patterns of positive responses could inform further protocol optimization. Additional analyses To address potential confounding factors due to the non-randomized design, multivariable logistic regression analysis was performed with adjustment for age, sex, and baseline systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate. The overall positive outcome was used as the dependent variable, and the study protocol group served as the primary independent variable. A sensitivity analysis was conducted using a stricter non-inferiority margin of − 7.5% to assess the robustness of the primary findings. To evaluate the diagnostic performance of the abbreviated BHUT phase for detecting orthostatic hypotension (OH), we reviewed all patients who were excluded from the primary analysis due to a confirmed diagnosis of OH. For these patients, we determined whether the diagnosis was made during the BHUT phase or only after nitroglycerin administration during the SNHUT phase. Statistical methods Continuous variables are presented as mean ± standard deviation (x̄ ± SD) and were compared using Student’s t-test. Categorical variables are reported as frequencies and percentages (n [%]) and were analyzed using chi-square or Fisher’s exact test, as appropriate. A two-tailed P-value < 0.05 was considered statistically significant. All statistical analyses were performed using R software (version 4.2.2; R Foundation for Statistical Computing) and MSTATA software (www.mstata.com). Results Population A total of 1,218 participants were enrolled, comprising 393 (32.3%) in the short-duration protocol group and 825 (67.7%) in the conventional protocol group. As summarized in Table 1, baseline demographic and physiological characteristics were well balanced between groups. The mean age of participants was 40 ± 19 years, with no significant intergroup difference in age distribution (p = 0.362). Gender distribution was also comparable (p = 0.415), with females representing 54.1% (n = 659) and males 45.9% (n = 559) of the total cohort. Table 1Baseline demographic and hemodynamic characteristics of study participantsCharacteristicTestp-value‡Overall, N = 1,218†Short-term, N = 393†Traditional, N = 825†Age40 ± 1939 ± 2040 ± 180.362Sex0.415Female659 (54.1%)206 (52.4%)453 (54.9%)Male559 (45.9%)187 (47.6%)372 (45.1%)SSBP120 ± 15119 ± 16120 ± 150.077DABP73 ± 1072 ± 1073 ± 100.397MABP88 ± 1188 ± 1188 ± 110.328HR76 ± 1376 ± 1376 ± 130.520SSBP supine systolic blood pressure, DABP supine diastolic blood pressure, MABP mean arterial pressure, HR heart rate† Data presented as mean ± standard deviation or n (%)‡ p-values calculated using Welch’s t-test (continuous variables) or Pearson’s chi-square test (categorical variables) Baseline demographic and hemodynamic characteristics of study participants SSBP supine systolic blood pressure, DABP supine diastolic blood pressure, MABP mean arterial pressure, HR heart rate † Data presented as mean ± standard deviation or n (%) ‡ p-values calculated using Welch’s t-test (continuous variables) or Pearson’s chi-square test (categorical variables) Hemodynamic parameters showed no significant differences: Mean systolic blood pressure: 120 ± 15 mmHg (p = 0.077); Mean diastolic blood pressure: 73 ± 10 mmHg (p = 0.397); Mean arterial pressure: 88 ± 11 mmHg (p = 0.328); Heart rate: 76 ± 13 bpm (p = 0.520). Analysis of Excluded Patients with Orthostatic Hypotension During the study period, a total of 1,321 consecutive patients underwent HUTT. After applying exclusion criteria, 103 patients were excluded from the primary non-inferiority analysis due to incomplete data (n = 12) or a confirmed diagnosis of non-vasovagal syncope (including orthostatic hypotension, psychogenic pseudosyncope, and orthostatic intolerance; n = 91). Among these 91 patients with non-vasovagal syncope, 58 had a confirmed diagnosis of orthostatic hypotension (OH). In the conventional protocol group (n = 825 initially enrolled), 47 patients were diagnosed with OH and excluded. Of these, 38 (80.9%) were detected during the 20-minute BHUT phase and 9 (19.1%) during the subsequent SNHUT phase. In the short-duration protocol group (n = 393 initially enrolled), 11 patients were diagnosed with OH and excluded. All 11 cases (100%) were detected during the 10-minute BHUT phase; no OH cases in the short-duration group were first diagnosed after nitroglycerin administration. Diagnostic yield and reaction patterns The primary non-inferiority analysis was met. The conventional protocol yielded an overall positive rate of 57.3%, compared to 53.4% in the short-duration group, resulting in an absolute difference of -3.9% (95% CI: -9.87 to 2.08). As the lower bound of the confidence interval (-9.87%) exceeded the pre-defined non-inferiority margin of -10%, the short-duration protocol was deemed statistically non-inferior (p = 0.20 for superiority test). A sensitivity analysis using a more stringent non-inferiority margin of -7.5% showed that the lower bound of the 95% CI (-9.87%) fell below this threshold. This indicates that the non-inferiority conclusion depends on the chosen margin; the short protocol cannot be declared non-inferior if a stricter definition of clinical acceptability is applied. A subgroup analysis indicated a significantly higher positive rate during the BHUT phase with the conventional protocol compared to the short-duration protocol (5.1% vs. 2.3%; p = 0.023). In contrast, positive rates during the subsequent SNHUT phase were identical between groups (52.2% in both arms; p = 0.98). The hemodynamic response types—mixed, cardioinhibitory, and vasodepressor—were similarly distributed between protocols, with no statistically significant differences detected in either the overall cohort or when stratified by test phase (BHUT or SNHUT; all p > 0.05; see Table 2). A trend toward a higher rate of vasodepressor responses during the SNHUT phase was observed in the short-duration group, though this did not reach statistical significance (14.5% vs. 10.7%; p = 0.053). Table 2Comparison of positive response rates and hemodynamic reaction patterns between protocolsCharacteristicConventional, N = 825Short-duration, N = 393p-value†Overall positivity n (%)473 (57.3%)210 (53.4%)0.2BHUT n (%)42 (5.1%)9 (2.3%)0.023SNHUT n (%)431 (52.2%)205 (52.2%)0.98Mixed form n (%)339 (41.1%)141 (35.9%)0.088BHUT n (%)29 (3.5%)8 (2.0%)0.16SNHUT n (%)310 (37.6%)133 (33.8%)0.21Cardioinhibitory form n (%)37 (4.5%)11 (2.8%)0.16BHUT n (%)4 (0.5%)0 (0%)0.31SNHUT n (%)33 (4.0%)11 (2.8%)0.29Vasodepressor form n (%)97 (11.8%)58 (14.8%)0.14BHUT n (%)9 (1.1%)1 (0.3%)0.18SNHUT n (%)88 (10.7%)57 (14.5%)0.053Mixed form: combined cardioinhibitory and vasodepressor responsesBHUT baseline head-up tilt test, SNHUT sublingual nitroglycerin head-up tilt test† p-values calculated using Pearson’s chi-square test Comparison of positive response rates and hemodynamic reaction patterns between protocols Mixed form: combined cardioinhibitory and vasodepressor responses BHUT baseline head-up tilt test, SNHUT sublingual nitroglycerin head-up tilt test † p-values calculated using Pearson’s chi-square test Multivariable logistic regression analysis To address potential confounding due to the non-randomized design, multivariable logistic regression was performed adjusting for age, sex, baseline systolic blood pressure (SSBP), diastolic blood pressure (DABP), mean arterial pressure (MABP), and heart rate (HR). After adjustment, the short-duration protocol remained non-inferior to the conventional protocol, with no significant difference in positivity rates (OR = 0.85, 95% CI 0.67–1.10, p = 0.215). Age was a significant predictor of HUTT positivity (OR = 1.01, 95% CI 1.00–1.02, p = 0.026), and male sex was associated with lower odds of a positive response (OR = 0.47, 95% CI 0.37–0.60, p < 0.001). Baseline blood pressure and heart rate were not independently associated with test outcome (all p > 0.05). Detailed results are presented in Table 3. Table 3Multivariable logistic regression analysis for predictors of HUTT positivityCharacteristic N Event NOR†95% CI†p-valueGroupConventional 825 473 Reference Reference Short-duration3932100.850.67, 1.100.215Age1,2186831.011.00, 1.020.026Sexfemale659426ReferenceReferencemale5592570.470.37, 0.60< 0.001SSBP1,2186830.980.97, 1.000.101DABP1,2186831.000.97, 1.030.972MABP1,2186831.000.96, 1.050.936HR1,2186830.990.98, 1.000.165† OR Odds Ratio, CI Confidence Interval Multivariable logistic regression analysis for predictors of HUTT positivity † OR Odds Ratio, CI Confidence Interval Time-to-positive response and cumulative event curves (Figs. 2 and 3) Cumulative Positive Case Number of the Short-duration Protocol. Before the dotted line: 10 minutes of BHUT; after the dotted line: 20 minutes of SNHUT. X-axis: time (min); Y-axis: cumulative number of positive cases Cumulative Positive Case Number of the Conventional Protocol. Before the dotted line: 20 minutes of BHUT; after the dotted line: 20 minutes of SNHUT. X-axis: time (min); Y-axis: cumulative number of positive cases. Over 95% of events occurred within the BHUT and the first 15 minutes of SNHUT, supporting truncation of the SNHUT phase without significant diagnostic loss The temporal distribution of positive responses during the SNHUT phase is summarized in Table 4. In both groups, the vast majority of positive responses (approximately 80–82%) occurred within the first 10 min following nitroglycerin administration. An additional 9.1–9.5% of responses were observed between 11 and 15 min. Beyond 15 min, only a small proportion of positive responses were recorded (1.9–3.8%), with no significant differences in temporal distribution between protocols across any time interval (all p > 0.05). Table 4Temporal distribution of positive responses during SNHUT phaseCharacteristicConventional Positive Group,N = 473†Short-duration Positive Group,N = 210†p-value‡Distribution of positive reaction stages0.035BHUT n (%)42 (8.9%)9 (4.3%)SNHUT n (%)431 (91%)201 (96%)Distribution of positive reaction time during SNHUT stages (min)≤ 10379 (80%)173 (82%)0.4911–1543 (9.1%)20 (9.5%)0.86≥ 169 (1.9%)8 (3.8%)0.14† BHUT phase: 20 min (conventional) vs. 10 min (short-duration); SNHUT phase duration: 20 min in both groups‡ p-values compare intergroup differences in response timing Temporal distribution of positive responses during SNHUT phase † BHUT phase: 20 min (conventional) vs. 10 min (short-duration); SNHUT phase duration: 20 min in both groups ‡ p-values compare intergroup differences in response timing Accordingly, truncation of the SNHUT phase at 10 min would have identified 86.3% and 88.9% of all positive responses in the short-duration and conventional groups, respectively—a difference that was not statistically significant (2.5%; p > 0.05). Extending the observation period to 15 min increased cumulative diagnostic yield to 98.9% in the short-duration group and 96.2% in the conventional group (p > 0.05), suggesting that prolonging testing beyond 15 min confers minimal incremental diagnostic value. As illustrated in Figs. 2 and 3, both protocols demonstrated closely aligned temporal profiles of response accumulation. During the BHUT phase, the increase in positive cases was gradual, with nearly identical trendlines (Fig. 2). Following nitroglycerin administration, a rapid rise in positive responses occurred beginning at 2 min, plateauing after 12 min. By 15 min post-administration, the cumulative curves stabilized, with minimal additional yield thereafter (Fig. 3). Discussion Time efficiency and diagnostic effectiveness This study demonstrates the diagnostic non-inferiority of the short-duration HUTT protocol (10-minute BHUT + 20-minute SNHUT) compared to the conventional 40-minute protocol, with similar overall positive rates (53.4% vs. 57.3%, p = 0.20) and no significant differences in hemodynamic response profiles. These findings provide new evidence supporting the optimization of SNHUT duration and merit further consideration in clinical practice. In contrast to the 20-minute “fast Italian protocol” (10-minute BHUT + 10-minute SNHUT) proposed by Russo et al. [23], our data indicate that truncating the SNHUT phase to 10 min would result in a 13.3% loss of positive cases. Notably, Glockler et al. [28] reported only a 1.5% decrease in positivity when reducing SNHUT from 15 to 10 min (245 positive cases; 80.1% positivity rate), a higher diagnostic yield than both Russo’s study and our own cohort. This discrepancy may reflect differences in test conditions and baseline population characteristics. Comparative data on SNHUT duration remain limited in the existing literature. The lower confidence limit of − 9.87% remained within the prespecified − 10% margin, indicating that any potential decrease in sensitivity is small enough to be clinically acceptable for routine use. Notably, the need for evidence-based optimization extends beyond diagnostic testing to VVS treatment. The recent COMFORTS-II trial, for example, demonstrated that thigh-high compression stockings did not significantly reduce syncope recurrence despite a strong physiological rationale [29]. Critically, our findings show that 96.2% of positive responses in the short-duration group (and 98.1% in the conventional group) occurred either during the BHUT phase or within 15 min of SNHUT initiation (Table 4). This supports the feasibility of shortening SNHUT from 20 to 15 min without significantly compromising diagnostic sensitivity. These results provide clinically relevant guidance on balancing procedural efficiency with diagnostic yield. The sensitivity analysis using a -7.5% non-inferiority margin did not support non-inferiority, indicating that the short protocol is associated with a modest reduction in diagnostic yield compared to the conventional protocol. However, the absolute difference in positivity rates was only − 3.9%, and the upper bound of the 95% CI (2.08%) even favored the short protocol. The lower bound of -9.87% represents the worst-case scenario, which exceeds the − 7.5% threshold but remains within the prespecified − 10% margin. We believe the − 10% margin is clinically appropriate for several reasons. First, the primary benefit of the short protocol—a 37.5% reduction in test duration—translates to meaningful improvements in patient comfort and laboratory throughput. Second, the 98.9% retention of positive findings when truncating SNHUT to 15 min (as shown in Table 4) suggests that the practical impact on diagnostic sensitivity is minimal. Third, the pattern of hemodynamic responses and the detection of all OH cases within the abbreviated BHUT (Sect. 3.2) indicate that the short protocol does not compromise the identification of clinically relevant subtypes. Therefore, while a statistically stricter margin would not be met, the trade-off between a small potential loss in sensitivity and substantial gains in efficiency supports the clinical utility of the short protocol in high-volume syncope centers. Hemodynamic mechanism and protocol design The BHUT phase remains essential for distinguishing VVS from delayed orthostatic hypotension (OH). Omitting this phase may increase false-positive rates [24]. While pharmacologic provocation accounts for approximately 85% of positive responses during SNHUT, current guidelines continue to emphasize the diagnostic utility of BHUT in detecting non-vasovagal forms of syncope, including orthostatic intolerance and autonomic dysfunction [10, 11]. Eliminating BHUT may thus result in underdiagnosis of these conditions. In this study, the 20-minute BHUT phase contributed 8.9% of positive cases in the conventional group, consistent with prior reports (e.g., 11% in [16]). Bartoletti et al. [30] reported a reduced diagnostic yield using an accelerated pharmacologic protocol (5-minute BHUT + 20-minute SNHUT) compared with standard testing. Although shortening BHUT to 10 min in our protocol reduced early-phase positivity (4.3% vs. 8.9%, p = 0.035), the overall positive rates remained comparable between groups (53.4% vs. 57.3%, p = 0.20). This suggests that the SNHUT phase may compensate diagnostically, consistent with findings from Forleo et al. [31]. An important consideration in shortening the BHUT phase is the potential for missed diagnoses of delayed orthostatic hypotension (OH). In our study, patients with confirmed OH were excluded from the primary non-inferiority analysis per protocol. However, examining these excluded cases provides valuable insight into the diagnostic performance of the abbreviated BHUT. Among the 58 patients diagnosed with OH during the study period, the conventional protocol (20-minute BHUT) detected 80.9% during the passive tilt phase, while the short protocol (10-minute BHUT) detected 100% of its OH cases within the abbreviated BHUT. No OH cases in the short-duration group were first diagnosed after nitroglycerin administration. The 9 OH cases in the conventional group that were diagnosed only during the SNHUT phase may represent a subset with very delayed orthostatic responses or those where nitroglycerin unmasked a latent susceptibility. Nevertheless, patients with a compelling clinical suspicion of autonomic failure may still require a longer baseline tilt or adjunctive beat-to-beat pressure monitoring, as the abbreviated BHUT risks overlooking delayed orthostatic hypotension that might inform treatment. The absence of such cases in the short-duration cohort—combined with the overall non-inferiority in VVS diagnosis—supports the clinical utility of the abbreviated protocol for routine syncope evaluation. Although not statistically significant, the numerically lower cardioinhibitory and higher vasodepressor proportions in the short-duration cohort suggest a shift in autonomic response pattern during briefer orthostatic stress. Whether this influences downstream management—such as pacemaker consideration or volume expansion—warrants targeted investigation. No increase in arrhythmias or adverse events was observed; however, safety data were limited and warrant further prospective evaluation. During the observation period, no sustained arrhythmias, severe hypotensive events requiring intervention, or drug-related adverse reactions were recorded in either cohort. Innovations and limitations The analysis was powered at 90.7% to detect non-inferiority within a − 10% margin, lending robustness to the negative finding. The short-duration HUTT protocol reduces total test time by 25% while improving patient tolerability [32], making it particularly suitable for high-volume syncope units. Applied to a laboratory performing 250 HUTTs annually, a 37.5% reduction translates to approximately 80 technician-hours saved per year. This study contributes three key innovations: (i) Beyond comparing overall positivity between protocols, we quantified incremental diagnostic loss at multiple SNHUT timepoints, generating data that complement international studies and address gaps in domestic literature; (i) Beyond comparing overall positivity between protocols, we quantified incremental diagnostic loss at multiple SNHUT timepoints, generating data that complement international studies and address gaps in domestic literature; (ii) The results empirically support truncating SNHUT to 15 min, clarifying the diagnostic implications of reduced testing time, which remained uncertain in Russo et al. [23]; (ii) The results empirically support truncating SNHUT to 15 min, clarifying the diagnostic implications of reduced testing time, which remained uncertain in Russo et al. [23]; (iii) Our findings validate not only the short-duration protocol’s diagnostic feasibility but also provide a foundation for further refinement of pharmacologic phase duration, informing future research and clinical workflows. (iii) Our findings validate not only the short-duration protocol’s diagnostic feasibility but also provide a foundation for further refinement of pharmacologic phase duration, informing future research and clinical workflows. Study limitations include: (i) The retrospective, single-center design with non-randomized group assignment based on test chronology, which may introduce selection bias due to local demographic and logistical factors; (i) The retrospective, single-center design with non-randomized group assignment based on test chronology, which may introduce selection bias due to local demographic and logistical factors; (ii) Intermittent blood pressure monitoring via electrocardiographic equipment may have delayed detection of hemodynamic changes, potentially affecting real-time diagnostic assessment. (ii) Intermittent blood pressure monitoring via electrocardiographic equipment may have delayed detection of hemodynamic changes, potentially affecting real-time diagnostic assessment. (iii) Due to the retrospective design, detailed data on patients' past medical history and concomitant medications—particularly those that might influence autonomic tone or hemodynamic responses—were not systematically available, representing a potential source of residual confounding. Pediatric patients were included with protocol modifications, but the small number of such cases precluded a meaningful subgroup analysis. Given that the study's primary objective was to evaluate diagnostic non-inferiority in a general adult population with unexplained syncope, the inclusion of a small pediatric subset is unlikely to have materially influenced the overall findings. Nevertheless, the absence of comprehensive medication data and the limited pediatric sample should be considered when interpreting the results, and future prospective studies with larger, more homogeneous cohorts are warranted. (iii) Due to the retrospective design, detailed data on patients' past medical history and concomitant medications—particularly those that might influence autonomic tone or hemodynamic responses—were not systematically available, representing a potential source of residual confounding. Pediatric patients were included with protocol modifications, but the small number of such cases precluded a meaningful subgroup analysis. Given that the study's primary objective was to evaluate diagnostic non-inferiority in a general adult population with unexplained syncope, the inclusion of a small pediatric subset is unlikely to have materially influenced the overall findings. Nevertheless, the absence of comprehensive medication data and the limited pediatric sample should be considered when interpreting the results, and future prospective studies with larger, more homogeneous cohorts are warranted. (iv) Among the 58 patients with confirmed orthostatic hypotension excluded from the primary analysis, all received appropriate clinical management. However, due to the small sample size and retrospective design, we could not systematically compare management strategies or outcomes between protocol groups based on the timing of OH diagnosis (BHUT vs. SNHUT). (iv) Among the 58 patients with confirmed orthostatic hypotension excluded from the primary analysis, all received appropriate clinical management. However, due to the small sample size and retrospective design, we could not systematically compare management strategies or outcomes between protocol groups based on the timing of OH diagnosis (BHUT vs. SNHUT). Conclusion The diagnostic performance of the short-duration HUTT protocol (10-minute BHUT + 20-minute SNHUT) was comparable to that of the conventional protocol (20-minute BHUT + 20-minute SNHUT), with no statistically significant differences in positive rates or response types (p > 0.05). Truncating the SNHUT phase to 15 min in the short-duration protocol preserved 98.9% of diagnostic sensitivity while reducing total test time by 37.5% compared to the conventional protocol. This optimization offers meaningful clinical benefit, particularly in high-throughput syncope evaluation settings. Supplementary Information Supplementary Material 1. Acknowledgements We sincerely appreciate the contributions of the medical and technical staff at the Department of Cardiovascular Medicine, The Third Affiliated Hospital of Sun Yat-sen University, for their invaluable assistance in patient data collection and clinical support. We are particularly grateful to our colleagues for their insightful discussions and constructive feedback during manuscript preparation. We also extend our deepest gratitude to the patients who participated in this study for their cooperation and trust. Finally, we acknowledge the editorial support provided by our peers in refining the language and structure of this paper. Abbreviations Head-up tilt test Baseline head-up tilt test Sublingual nitroglycerin head-up tilt test Vasovagal syncope Transient loss of consciousness Orthostatic hypotension Supine systolic blood pressure Supine diastolic blood pressure Mean arterial pressure Heart rate Authors’ contributions Saijia Yang (First Author): Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing – original draft, Writing – review & editing. Yuen Liang: Data curation, Investigation, Methodology, Project administration, Resources, Validation, Visualization. Zhuoshan Huang: Writing – review & editing, Investigation, Data curation. Lin Wu: Writing – review & editing, Investigation, Data curation. Ruimin Dong: Writing – review & editing, Investigation, Data curation. Kemei Liu: Writing– review & editing, Investigation, Data curation. Shan Cao: Writing–review & editing, Investigation, Data curation. Ling Jiang (Corresponding Author): Conceptualization, Data curation, Project Administration, Investigation, Supervision, Writing - Review & Editing. Xujing Xie (Corresponding Author): Conceptualization, Funding Acquisition, Project Administration, Resources, Supervision, Writing - Review & Editing. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability The data that support the findings of this study are available from the corresponding author, upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Approval No. [2023]193-01; date: August 3, 2023). The need for informed consent was waived by the same Ethics Committee due to the retrospective nature of the study. The study was conducted in accordance with the principles of the Declaration of Helsinki. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Saijia Yang and Yuen Liang contributed equally to this work. Contributor Information Ling Jiang, Email: blueling012@163.com. Xujing Xie, Email: xiexj@mail.sysu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The data that support the findings of this study are available from the corresponding author, upon reasonable request.